Surgical management in epithelial ovarian cancer (EOC) has a significant impact in overall survival and progression-free survival. The Brazilian Society of Surgical Oncology (BSSO) supported a taskforce of experts to reach a consensus: experienced and specialised trained surgeons, in cancer centres, provide the best EOC surgery. Laparoscopic and/or radiological staging prognosticates the possibility of complete cytoreduction (CC0) and helps to reduce unnecessary laparotomies. Surgical techniques were reviewed. Multidisciplinary input is essential for treatment planning. Quality assurance criteria are proposed and require national consensus. Genetic testing is mandatory. This consensus states the final recommendations from BSSO for management of EOC.
Introduction
Ovarian cancer is associated with 40-50% mortality, as it is frequently diagnosed in advanced stages of the disease.
Optimal surgical management is a predictor of overall survival (OS) and progression-free survival (PFS) in EOC. Complete cytoreduction (R0 or CC0) may involve complex surgical procedures such as peritonectomy and diaphragmatic resections. This is best achieved by a multidisciplinary team of experienced surgeons in cancer care centres. Centralisation of treatment, where evidencebased approaches are offered, has become important over the years. 1, 2 New technology and human resources should be distributed according to levels of complexity of surgery. 3 In the absence of a formal surgical specialty focused on gynaecological cancer treatment, scientific task forces may play an important educational role. More than 200 Brazilian medical professionals have been collaborating to develop a digital network for better cancer care. The Brazilian Society of Surgical Oncology created a taskforce on EOC with the aim of establishing minimum standards for treatment.
Method
This initiative united experts representing major surgical and oncological Brazilian societies from different regions and institutions. Over a 10-month period, 17 leading experts (16 surgeons included) from 12 cancer centres attended meetings, web meetings, held digital discussions, and wrote electronic positional papers. A comprehensive literature review of studies published between January 2005 and June 2017 was carried out. This open and collaborative approach allowed all members to participate and express criticism, in addition to a scientific review adjusted to Brazilian current standards. Key questions were answered as consensus statements. Levels of evidence were designated according to a conventional classification, modified from NCCN guidelines (Table 1) . 4 
What is the current situation of EOC?
In 2012, according to GLOBOCAN, 238 719 new EOC cases were detected and 151 917 women died from the disease. 5 It is the seventh most common cancer and the eighth cause of death from cancer in women. 6 EOC constitutes around 90% of malignant ovarian neoplasms. 7 It was estimated in Brazil in 2016 that there would be 6150 new cases of EOC and 3283 deaths due to the disease. It is the seventh most common cancer in Southern Brazilian women. 8 There is incomplete reporting in Brazil regarding stages at diagnosis, modalities of treatment, access to medication and surgical standards. Oncological data from São Paulo State showed that EOC cases correspond to 3.2% of total nonskin cancer diagnosis in women. The mean time for diagnosis is 14 days and for primary treatment from 12 days (at cancer centres) to 70 days (outside cancer centres). 9 Since 2012, all Brazilian citizens have had the right to start treatment for first-stage cancer within 60 days of the diagnosis. Advanced-stage EOC patients cannot cope with such a long waiting time. Centralisation of EOC cases in cancer centres provides better time intervals and is supported by this panel.
What institutions and surgeons should provide surgical management for EOC patients?
Consensus: Patients with high risk or with an established diagnosis of EOC should be evaluated by a specialised gynaecological oncologist or a surgical oncologist focused on gynaecological cancer treatment. First-stage surgery should be performed by a high-volume specialist (more than ten procedures per year), preferably in a high-volume hospital (20 or more cases per year) (Category 2).
EOC mortality depends on a multidisciplinary surgical team operating in a tertiary hospital or a cancer centre. Patients with EOC treated by gynaecological oncologists have superior outcomes when compared with those treated by general gynaecologists and general surgeons. 10 Guideline-adherent cancer care is associated with highvolume hospitals (20 or more cases per year; 50.8 versus 34.1%; P < 0.001) and high-volume physicians (ten or more cases per year; 47.6 versus 34.5%; P < 0.001). Adherence to NCCN guidelines for treatment of EOC is correlated with improved survival and may be a useful process to measure the quality of cancer care. 2, 11 What are the best imaging tools prior to surgical management?
Consensus: All patients should have a chest CT scan and a complete abdominal imaging acquisition, CT or MRI (Category 2). Relative contraindications to surgery should be discussed in a multidisciplinary tumour board meeting and preoperative surgical planning (Category 2).
Imaging methods are useful for diagnosis and to assess the extent of disease. Diffusion magnetic resonance (MRI) is the best preoperative alternative to evaluate peritoneal disease compared with ultrasound (USG), tomography (CT) or PET-CT. Diffusion MRI is more accurate in detecting peritoneal disseminated disease, hepatic and splenic metastasis, and in predicting resectability. 12 Radiological contraindications to primary debulking surgery include the following: massive mesenteric infiltration and retraction with segmental small bowel subocclusions massive porta hepatis or hepatic round ligament infiltration liver or lung parenchymal multiple metastases omental cake with clear infiltration of the lesser gastric curvature (demanding total gastrectomy with en bloc transverse colectomy). What are the best tools for selection of patients for surgery?
Consensus: A combination of performance status, age, and tumour burden should be considered for patient selection for primary surgery compared with neoadjuvant chemotherapy followed by interval debulking surgery strategies (Category 2). Laparoscopic evaluation of tumour spread and resectability is recommended as a feasible tool that may prevent unnecessary laparotomies (Category 2). Adequate patient selection for EOC surgical treatment requires individualised planning that takes into account the individual functional evaluation and disease extension. Preoperative performance status (PS), 14, 15 rather than age, prognosticates perioperative morbidity and mortality, the ability to complete primary therapy, overall survival (OS), and progression-free survival (PFS). 16 In addition, nutritional, psychological, anaesthetical risk, and comorbidities should be addressed and may impact surgical results. A multidisciplinary evaluation is paramount, especially when a multivisceral resection is planned for a complete resection (R0). 17 Evaluation of adequate abdominal peritoneal spread may predict resectability and surgical complexity. In 2005, Sugarbaker et al. 18 standardised a peritoneal cancer index (PCI) in 13 different abdominal regions, each classified as 0 (no tumour), 1 (tumours up to 0.5 cm), 2 (tumours up to 5 cm), or 3 (tumour of more than 5 cm at the largest diameter). 18 This index was created for an exploratory laparotomy in carcinomatosis independently of the primary tumour. A PCI greater than 20 may indicate the necessity for a more extensive surgical procedure, and neoadjuvant therapy should be considered.
A laparoscopic score was created by Fagotti et al. in 2006, for EOC carcinomatosis evaluation 19, 20 and was updated in 2015. 21 It is a binary system, in which each of the following laparoscopic parameters score two points: massive peritoneal involvement and/or a miliary pattern parietal peritoneal carcinomatosiswidespread infiltrating carcinomatosis, and/or confluent nodules to most parts of the diaphragmatic surface; tumour diffusion along the omentum up to the large stomach curvature possible large/ small bowel resection (excluding rectosigmoid involvement, where posterior exenteration is considered a standard surgical procedure) obvious neoplastic involvement of the stomach, and/or lesser omentum, and/or spleen liver surface lesions larger than 2 cm As mesenteric retraction and miliary carcinomatosis on the serosa of the small bowel are widely recognised as absolute criteria of unresectability, these criteria were excluded from the score. 21 The higher the score, the less likely that the patient will be optimally debulked. Patients with ten or more points had no chance of complete cytoreduction with primary surgery; of those with a score of 8, only 8.3% will achieve complete cytoreduction. 21 The decision to perform extensive surgical procedures must consider:
extensive preoperative planning multidisciplinary meeting PS and clinical/anaesthetical contraindications for primary debulking surgery (PDS) carcinomatosis extension that does not allow a complete PDS, assessed by a trained surgical team
What are the main surgical objectives?
Consensus: Complete R0 resection is the main goal, with balanced morbidity (Category 1). Primary debulking surgery is the mainstay approach (Category 1). Patients without good surgical conditions or excessive tumour burden should be considered for neoadjuvant chemotherapy and interval debulking surgery (Category 2).
Surgical cytoreduction in the treatment of EOC has been the object of study since Griffiths in 1975, 22 who related greater survival with smaller residual lesion size. In 1982, Blythe et al. 23 demonstrated greater survival in a group of patients with residual lesions of up to 2 cm. In 1986, Piver 24 described the possibility of achieving this pattern of cytoreduction in 75% of stage III and IV patients. The GOG study published by Hoskins et al. in 1994 25 concluded that residual disease of up to 2 cm was correlated with a better patient survival overall. In 2007, the German Group AGO-OVAR 26 published a prospective randomised trial demonstrating that residual disease is an independent prognostic, and that patients with no residual disease had a better prognosis. In 2009, du Bois et al. 27 published data from a combined exploratory analysis of three prospective randomised phase 3 trials. The primary goal of EOC cytoreductive surgery is no visible residual disease.
As previously mentioned, the PCI of Sugarbaker 28 is a good tool for describing the extent of disease and the residual tumour volume (Table 2 ). Two major randomised trials proved that in patients with stage IIIC-IV EOC, PDS patients achieved oncological outcomes comparable to interval debulking surgery (IDS) patients. 29, 30 Most patients from both studies were ECO grade PS0 or 1. PDS was related to more multiorganic resections and morbidity. In both studies, R0 rates in both arms were comparable to those in nonspecialists performing surgery in nonspecialised centres (18.3 and 16% upfront, versus 48 and 43% neoadjuvant chemotherapy, respectively). Median OS was 29 and 30 months, and 22.6 and 24.1 months, respectively. 29, 30 The morbidity of an extensive cytoreductive surgery varies from 30 to 60% and should be balanced, with a target of starting adjuvant chemotherapy within 4-6 weeks after an operation.
Although complex and extensive surgical approaches may enhance rates of completeness of cytoreduction, tumour load remains an independent poor prognostic factor and probably reflects a more aggressive biological behaviour. 31, 32 What is the role of chemotherapy in EOC and how does it fit with surgical treatment?
Consensus: Chemotherapy is offered to most patients with EOC. Platinum-based regimens are preferred as a first-line therapy, and for recurrence in platinum-sensitive or platinum-naive patients (Category 1). Intraperitoneal (IP) chemotherapy can be offered to selected patients with primarily complete cytoreduction (Category 1).
Patients with initial EOC stage I and grade 3, or stage IC should be completely staged, and will benefit from three cycles of platinum-based chemotherapy. 33 When considering a serous histology, there is a potential benefit from six cycles for these early-stage, high-risk patients. 34 Primary debulking surgery followed by platinum-based systemic chemotherapy is the initial recommendation for medically fit patients with EOC stages II-IV. Adjuvant therapy is platinum-based and is less morbid when carboplatin is associated with paclitaxel for a mean of six cycles. 35 The combination of pegylated liposomal doxorubicin with carboplatin was not superior to a standard-care carbo-taxol regimen. 36 Patients with bulky stages III-IV disease, poor surgical candidates, and/or tumour load unlikely to be optimally debulked, as assessed by a specialist gynaecological oncologist, are potential candidates for IDS. Morbidity is reduced in this approach, with a comparable DFS and OS. 29, 37 Intraperitoneal (IP) chemotherapy combined with systemic platinum-based chemotherapy may confer an OS benefit for patients medically fit enough to receive adjuvant therapy. 38 This effect is associated with the number of cycles, and toxicities are frequently related to fatigue, neuropathy, renal function, and abdominal discomfort, and are catheter-related. 39 Hyperthermic perioperative chemotherapy (HIPEC) with cisplatin (100 mg/m 2 ) can be offered to IDS patients completely or optimally debulked. In a recent RCT, morbidity was comparable and a significant 3.5-month median DFS improvement was achieved with HIPEC (14.2 versus 10.7 months). 40 HIPEC seems to be a promising tool. It can be an option for medically fit patients, treated in centres of excellence, by trained surgeons, after a multidisciplinary tumour board meeting and at least stable disease after neoadjuvant chemotherapy (Category 3).
What are the main quality characteristics to be assessed?
Consensus: Quality assessment is paramount for achieving better outcomes. PDS (>50%), procedures performed by specialists (>90%), rate of R0 resections (>65%), completeness of surgical, pathological and morbidity records, operative structure, and multidisciplinary treatment planning are the recommended performance indicators for quality assurance in EOC surgery (Category 2).
Quality of care is defined as 'the degree to which health services for individuals and populations increase the likelihood of desired health outcomes and are consistent with current professional knowledge'. Good quality means providing patients with appropriate services in a technically competent manner, with good communication, shared decision-making, and cultural sensitivity. 41 In EOC, the quality of the surgical procedures (staging and cytoreductive surgeries) is the cornerstone of patient care. Although solid data have shown that patients treated by gynaecological oncologists and in specialised centres have better outcomes, heterogeneity in surgical care still exists. [42] [43] [44] The identification of surgical quality indicators is challenging due to the lack of qualitative parameters. 45 In 2009, the European Organisation for Research and Treatment of Cancer (EORTC) 46 proposed quality indicators for staging laparotomy and for PDS for stage III-IV EOC. In 2016, the European Society of Gynaecological Oncology (ESGO) 47 proposed a complete list that included ten quality indicators (QIs) for advanced EOC surgery that can be used to audit and improve clinical practice (Table 3) . 48 
Surgical major technical issues
Consensus: Advanced surgical skills provided by surgical specialists in a referral centre with a multidisciplinary approach are the best combination to reduce morbidity and enhance surgical objectives of cytoreduction (Category 2).
Surgeons must provide a detailed surgical report describing the extent of disease before debulking pelvis, mid-abdomen, and/or upper abdomen, and the amount of residual disease in the same areas after debulking. Reports of complete or incomplete resection, and if it is incomplete the reasons for this, should indicate the size of the major lesion and total number of lesions (Category 2).
Surgical aims in EOC include diagnosis for adnexal mass or carcinomatosis, accurate staging for limited disease, peritoneal extension assessment or cytoreduction for advanced or metastatic disease.
Patient and anaesthesia requirements
Any institution interested in performing EOC surgery must have an intermediate high-dependency care facility and access to an intensive care unit in the centre. An active perioperative management programme should include preoperative nutritional and haemoglobin optimisation, with iron deficit correction. According to the current guidelines, 
90%
Operative report is structured. Size and location of disease at the beginning of the operation must be described. All the areas of the abdominal cavity must be described. If applicable, the size and location of residual disease at the end of the operation, and the reasons for not achieving complete cytoreduction must be reported Minimum required elements in pathology reports ≥90%. The flexibility within this target reflects situations where it is not possible to report all components of the data set due to poor quality of specimen Patients with good PS, but high tumour load, should also be scheduled for staging laparoscopy only. The multidisciplinary team then provides details regarding organs to be spared or resected, and morbidity and mortality in PDS versus IDS.
Patients with a good PS and potentially resectable disease, with few or no organs to be resected, can be scheduled for staging laparoscopy followed by cytoreductive procedure, under a single anaesthetical procedure.
Adequate patient selection reduces unnecessary complex anaesthetical procedures for patients that are not suitable for a PDS, and improves operating room timetables. Diagnostic laparoscopy with a Fagotti score 49 may improve selection to PDS or IDS.
Surgery should start with an umbilical incision for laparoscopic inspection. A second port is inserted in the lower abdomen to help with bowel manipulation. In the case of advanced disease, an extra 5-mm port should be inserted in the midline in the upper abdomen.
50
Role of surgical staging For initial EOC, stages I and II, the accuracy and adequacy of surgical staging by laparotomy or by minimally invasive surgery (MIS) appear to be oncologically equivalent. MIS approaches result in lower postoperative complication rates, shorter hospital stay, 51 and less blood loss. 52 However, intraoperative tumour rupture has been reported to occur more frequently in patients undergoing laparoscopy during an MIS learning curve. 53 There are no randomised data comparing laparotomy with laparoscopy staging for EOC. 54 Surgical technical details Surgical staging starts with aspiration of ascites or peritoneal lavage for peritoneal cytological examinations and complete peritoneal surface evaluation, followed by excision of any peritoneal surface or adhesion suspicious for metastasis. In the absence of any suspicious areas, random peritoneal biopsies should be taken from the pelvis, paracolic gutters, and both diaphragmatic surfaces.
Bilateral salpingo-oophorectomy and hysterectomy should be performed, making every effort to keep an encapsulated mass intact during removal. For selected patients desiring to preserve fertility, uterine and contralateral adnexal preservation may be considered. Infracolic omentectomy should be performed. 55 Retroperitoneal lymphadenectomy includes removal of nodal tissue from the vena cava and the aorta bilaterally, up the left renal vein. Systematic pelvic lymphadenectomy includes nodal tissue from the common, internal, and external iliac vessels and obturator fossa, superficial to the obturator nerve. In a recent trial presented in an oncological meeting (LION trial, ASCO 2017, Chicago, IL, USA) systematical lymphadenectomy increased morbidity without OS benefit for advanced stage disease and, in the absence of macroscopic and preoperative imaging of suspicious lymph nodes, after complete cytoreductive surgery. The goal of cytoreductive surgery in EOC should be R0 resection. 27 Therefore, advanced techniques of peritoneal stripping, multivisceral resection, and upper abdominal management 56, 57 have been standardised and combined with surgical staging techniques (Tables 4 and 5) .
Video-assisted thoracic surgery (VATS) should be considered for patients with advanced EOC and pleural effusion. VATS allows assessment of intrathoracic disease and may select candidates for PDS with possible intrathoracic cytoreduction versus IDS. Bilateral salpingo-oophorectomy and comprehensive surgical staging*** Stages I-IV good performance status and mild* to moderate tumour load, no fertility-preserving desire Total hysterectomy with bilateral salpingo-oophorectomy and comprehensive surgical staging*** and debulking with complete (or optimal) cytoreduction as a surgical goal Stages III-IV high tumour load and/or poor surgical candidate** Neoadjuvant chemotherapy followed by surgical reassessment for interval debulking surgery *Adnexal mass with limited disease and no fertility desire could benefit from frozen section and a proceed-as-indicated approach. **Poor surgical candidates may benefit from percutaneous biopsy with histological diagnosis or a combination of diagnostic cytology and CA125/CEA ratio >25. ***Laparoscopic or robotic approach acceptable and advisable, preserving oncological principles of avoiding tumour spillage and performance of a comprehensive peritoneal cavity inspection.
61,62

Is genetic counselling mandatory?
Consensus: There is a formal recommendation to refer all patients with EOC to a genetic counselling evaluation, regardless of age or family history (Category 2). In the absence of a specialised geneticist, all oncologists should be trained to offer BRCA 1 and 2 testing (Category 2).
Approximately 24% of all patients with nonmucinous ovarian, peritoneal or fallopian tube carcinoma carried germline loss-of-function mutations, 18% in BRCA1 or BRCA2. 63 More than 30% of patients have no family history of breast or ovarian carcinoma, and more than 35% are 60 years or older at diagnosis. 63 Among EOCM Brazilian patients unselected for family history of cancer, approximately 19% are BRCA1/2 germline mutation carriers. 64 Therefore, comprehensive genetic testing for inherited carcinoma is highly recommended for all women with ovarian, peritoneal or fallopian tube carcinoma, regardless of age or family history.
The overall rearrangement frequency is relatively uncommon in Brazil, 64, 65 but if NGS or Sanger sequencing does not confirm single nucleotide variants, or small insertions and deletions, then array comparative genomic hybridisation or multiplex ligation-dependent probe amplification should be used for rearrangement diagnosis.
Despite negative BRCA test results, if clinicians remain suspicious of another hereditary cancer syndrome, a multigene panel testing should be considered. 66 Risk-reducing salpingo-oophorectomy remains the standard care for reducing EOC mortality among high-risk women. Salpingectomy in women BRCA carriers should be offered only in a clinical trial. 67 Is there a role for surgery in EOC recurrence?
Consensus: All patients with recurrence should be referred to a multidisciplinary tumour board for case review and best management decision (Category 2).
Cases for salvage surgery should be offered for surgically fit patients, considering the following: platinum sensitivity, PS, tumour load, resectability, and the absence of ascites. 68 Platinum-sensitive patients with relapses are potential candidates for surgery and should be referred for a specialised surgical evaluation. R0 resection in platinum-sensitive patients significantly improves OS. When it is not The greater omentum is elevated off the transverse mesocolon by stripping the entire surface of the mesocolon. The dissection includes separation of the specimen from the gastroepiploic vessels (preserved if possible) and division of the short gastric vessels. The omentum is dissected and detached from the splenic hilum and the anterior surface of the pancreas. Meticulous dissection of the omentum is essential for complete tumour removal Epigastric peritonectomy
The falciform ligament is separated from the umbilicus along with the anterior peritoneum and resected flush with the liver surface to include the ligamentum teres hepatis. A bridge of liver may be divided to access the left portal vein if necessary Right hemidiaphragmatic peritonectomy Diaphragmatic peritoneum is stripped along its entirety after making a cruciate incision in the anterior peritoneum. The peritonectomy may include stripping the Gerota fascia, the right adrenal gland surface, and the liver Glisson capsule. A ventral liver mobilisation technique for cytoreduction of diaphragmatic tumours with involvement of the liver is feasible and safe. Recognition of upper abdominal anatomy and liver mobilisation manoeuvres are fundamental to allow exploration and debulking of the diaphragm, reducing the risk of major vessel injuries (retrohepatic caval vein, hepatic hilum, suprahepatic veins, diaphragmatic vessels). 58 The specific sequence of liver mobilisation varies from patient to patient according to the tumour distribution and extension. 58 The retrohepatic inferior vena cava (IVC) is the medial border of the dissection. This surgical procedure can be adopted for the management of bulky diaphragmatic tumours in select patients 59 Left hemidiaphragmatic peritonectomy
The upper left portion of a cruciate incision is used to initiate the left hemidiaphragmatic peritonectomy. Complete stripping of the diaphragmatic fibres with skeletonisation (or ligation) of the inferior phrenic vessels may be undertaken. Dissection may include stripping the adrenal gland surface and Gerota fascia Lesser omentum resection
The hepatoduodenal ligament and the pars flaccida are dissected from the caudate lobe of the liver and the porta hepatis. Careful dissection of the coeliac axis branches and the right gastric arteries can elevate the tumour off the lesser omentum. The IVC bursa is occasionally stripped, using the IVC, caudate lobe of the liver, and the left limb of the right crus as anatomical landmarks Pelvic peritonectomy Pelvic peritonectomy includes resection of the anterior peritoneum with or without the urachus and the medial umbilical ligaments. A rectal and Douglas pouch shaving may reduce morbidity with a complete pelvic peritoneal clearance. Visceral resections of the uterus and ovaries are performed as necessary Anterior peritonectomy Scar excision and resection of the anterior peritoneum are carefully undertaken with preservation of the rectus muscle fascia as the procedure starts. This becomes contiguous with the other peritonectomy specimens in the presence of extensive peritoneal disease 60 feasible, optimal cytoreduction (0.5-1 cm residual tumour) should be considered. 69 When is palliative surgery indicated?
Consensus: Patients with significant symptoms that may be relieved by surgery should be referred for surgical evaluation and a tumour board meeting (Category 2). Patients with pain due to a resectable metastatic tumour or bleeding may benefit from palliative surgery. 70 Patients with EOC frequently experience bowel occlusion. Palliative surgery for bowell obstruction (limited resection and/or stoma) is indicated in surgically fit patients with a segmental occlusion and without extensive carcinomatosis, and preferably with no ascites. 71 Incomplete resections are not curative and may adversely impact time to systemic therapy and quality of life, due to surgical complications.
Future perspectives and key questions
This consensus supports significant policies for the public healthcare system in the country, including:
centralisation of EOC cases in cancer centres multidisciplinary tumour boards and patient-driven decisions quality assurance in EOC surgery Some questions will need to be addressed after this consensus:
is 
Conclusions
Surgery has a significant impact on EOC outcomes. This consensus provides answers to key questions related to surgical management of patients with EOC. The surgical aim is complete cytoreduction with acceptable morbidity. This document is a Brazilian guideline and may serve as a tool for governmental decisions regarding new technology and resource acquisition.
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